| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/IMJ.12381 |
| P698 | PubMed publication ID | 24754684 |
| P50 | author | Claire M. B. Holloway | Q83578946 |
| P2093 | author name string | S Cheruvu | |
| P2860 | cites work | Coronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic Individuals | Q22252997 |
| Interventions to reduce harm from continued tobacco use | Q24244287 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Inflammation, coagulation and cardiovascular disease in HIV-infected individuals | Q28483645 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991. Presentation, diagnosis, treatment, and 28-day case fatality of 3991 events in men and 1551 events in women | Q33174642 | ||
| Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? | Q33184007 | ||
| Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). | Q33404972 | ||
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. | Q33576435 | ||
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study | Q33602915 | ||
| Impact of HIV infection on diastolic function and left ventricular mass | Q33721647 | ||
| Systematic review of guidelines on imaging of asymptomatic coronary artery disease | Q33865423 | ||
| The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations | Q46789897 | ||
| Diastolic stress echocardiography detects coronary artery disease in patients with asymptomatic type II diabetes. | Q51586120 | ||
| Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients. | Q51605887 | ||
| Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. | Q51625767 | ||
| Cardio- and cerebrovascular events in HIV-infected persons. | Q53286263 | ||
| Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil. | Q54575438 | ||
| Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 | ||
| Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study | Q57313883 | ||
| Protease inhibitors and cardiovascular outcomes in patients with HIV-1 | Q57955538 | ||
| Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection | Q58375394 | ||
| Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the | Q58375437 | ||
| Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. | Q33962303 | ||
| Coronary CT angiography versus standard evaluation in acute chest pain | Q34290173 | ||
| Smoking behaviors in a community-based cohort of HIV-infected indigent adults | Q34342328 | ||
| Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System | Q34564981 | ||
| Immunologic basis of cardiovascular disease in HIV-infected adults | Q34638205 | ||
| Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals | Q34800277 | ||
| Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. | Q35002031 | ||
| Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study | Q35166149 | ||
| Cigarette smoking and HIV: more evidence for action | Q35640008 | ||
| Stress echocardiography: current methodology and clinical applications | Q36152091 | ||
| Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy | Q36651656 | ||
| SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen | Q36811227 | ||
| 64-slice CT for diagnosis of coronary artery disease: a systematic review | Q37240140 | ||
| Cardiac manifestations of HIV infection: an African perspective | Q37357024 | ||
| HIV infection and the risk of diabetes mellitus. | Q37365031 | ||
| Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 | ||
| Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients | Q37434889 | ||
| Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy | Q37496608 | ||
| Abacavir and cardiovascular risk: reviewing the evidence | Q37762482 | ||
| The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care | Q38023235 | ||
| Cardiovascular complications of HIV infection and treatment | Q38040481 | ||
| HIV and coronary heart disease: time for a better understanding | Q38078094 | ||
| HIV-related mechanisms in atherosclerosis and cardiovascular diseases | Q38105203 | ||
| Usefulness of 64-slice cardiac computed tomographic angiography for diagnosing acute coronary syndromes and predicting clinical outcome in emergency department patients with chest pain of uncertain origin | Q42011258 | ||
| Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study | Q42282082 | ||
| Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study | Q42992133 | ||
| Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial | Q43259468 | ||
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? | Q44055963 | ||
| Insulin and carbohydrate dysregulation | Q44372655 | ||
| Impact of HIV infection and HAART on serum lipids in men. | Q44473694 | ||
| Combination antiretroviral therapy and the risk of myocardial infarction | Q44662157 | ||
| Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women | Q44696436 | ||
| Coronary calcium score and computed tomography coronary angiography in high-risk asymptomatic subjects: assessment of diagnostic accuracy and prevalence of non-obstructive coronary artery disease | Q44831440 | ||
| Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. | Q45740345 | ||
| Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study | Q46175058 | ||
| Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy | Q46378097 | ||
| Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study | Q46505818 | ||
| Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study | Q46546975 | ||
| Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study | Q46549312 | ||
| P433 | issue | 4 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 315-324 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Internal Medicine Journal | Q15749165 |
| P1476 | title | Cardiovascular disease in human immunodeficiency virus | |
| P478 | volume | 44 |
| Q36168754 | Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS. |
| Q51779710 | Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection. |
| Q59340042 | Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race |
| Q38936060 | Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes |
| Q35826419 | Clinical Outcomes of Patients with HIV Undergoing Lead Extraction for Infectious and Noninfectious Indications |
| Q38988925 | Direct Targeting of Macrophages With Methylglyoxal-Bis-Guanylhydrazone Decreases SIV-Associated Cardiovascular Inflammation and Pathology |
| Q40144330 | Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. |
| Q40565869 | Screening and risk assessment for coronary artery disease in HIV infection: an unmet need |
Search more.